Last updated: February 3, 2026
Executive Summary
OMNIPAQUE 140 (iodixanol injection, 140 mg/mL) is a widely used contrast agent for diagnostic medical imaging, particularly in computed tomography (CT) scans. The product’s stability, safety profile, and established regulatory approvals contribute to its consistent demand. This analysis provides a comprehensive overview of OMNIPAQUE 140’s current market landscape, growth potential, competitive positioning, and financial trajectories, offering vital insights for stakeholders and investors in pharmaceutical and healthcare sectors.
1. Market Overview
1.1. Product Profile and Indications
- Active Ingredient: Iodixanol, non-ionic, iso-osmolar radiocontrast agent.
- Uses: Primarily used in enhanced diagnostic imaging procedures such as CT angiography, CTO scans, and angiography.
- Advantages: Reduced risk of adverse reactions compared to ionic contrast agents, especially in patients with compromised renal function.
1.2. Key Market Metrics
| Parameter |
Data/Estimate |
| Global contrast media market size (2022) |
USD 4.6 billion [1] |
| CAGR (2023-2028) |
~5.1% |
| OMNIPAQUE’s share of contrast agent market |
Estimated at 17–20% based on revenue [2] |
| Major geographies |
North America, Europe, Asia-Pacific, LATAM |
1.3. Regulatory Status
- Approval: FDA (USA), EMA (Europe), PMDA (Japan) – long-established approvals.
- Patent Status: Patent expiration occurred in mid-2010s; now off-patent, enabling broader manufacturing.
2. Market Dynamics
2.1. Drivers of Market Growth
| Drivers |
Impact & Evidence |
| Aging Population |
Increased diagnostic procedures, especially in geriatrics [3] |
| Rising Prevalence of Chronic Diseases |
CAD, cancer, neurological disorders fuel demand for imaging [4] |
| Advancements in Imaging Technologies |
Increased resolution and diagnostic accuracy and volume [5] |
| Growing Healthcare Infrastructure |
Investment in diagnostics capacity across emerging markets [6] |
2.2. Constraints and Challenges
| Constraints |
Impact & Evidence |
| Regulatory Constraints and Reimbursement Policies |
Variability limits market penetration; reimbursement delays [7] |
| Competition from Alternative Agents |
Increased use of MRI contrast agents (e.g., gadolinium-based) [8] |
| Safety and Side Effect Concerns |
Rare adverse events (e.g., nephrotoxicity) influence brand loyalty [9] |
2.3. Competitive Landscape
| Competitors |
Product/Indication |
Market Share Estimate |
Key Differentiators |
| GE Healthcare |
Omnipaque (iohexol) |
~23% |
Widely recognized, strong global distribution network |
| Bayer (now part of Bayer AG) |
Ultravist (iopromide) |
~20% |
Cost-effective, extensive R&D |
| Guerbet |
Lipiodol, Visipaque (iodixanol) |
Mixed |
Focus on iso-osmolar contrast agents, higher safety profile |
| Others |
Iohexol, iopamidol, ioversol |
Remaining share |
Variations in osmolarity, cost, and distribution |
Note: OMNIPAQUE primarily competes on safety and differentiation through its iso-osmolar formulation.
3. Financial Trajectory and Investment Outlook
3.1. Revenue Projections & Growth
| Year |
Estimated Revenue (USD billion) |
Growth Rate |
Key Assumptions |
| 2023 |
$650–700 million |
— |
Stabilized due to mature market presence |
| 2024–2028 |
CAGR of 3–5% globally |
3–5% |
Conservative growth driven by aging populations and emerging markets expansion |
3.2. Revenue Drivers and Risks
- Expansion in Emerging Markets: Infrastructure investments, increasing healthcare access expected to fuel demand.
- Shift to MRI: Growing preference for MRI imaging, which uses different contrast agents, may limit CT contrast agent growth.
- Patent and Pricing Pressures: Sharp increases in generic manufacturing have heavily compressed margins.
- Regulatory Forecasts: Stricter safety regulations could influence formulation standards and pricing.
3.3. Cost Structure & Profitability
| Cost Element |
Approximate Percentage of Revenue |
Notes |
| Manufacturing & Raw Materials |
30–40% |
Cost inflation driven by raw material prices (iodine, solvents) |
| R&D |
5–10% |
Declined post-patent expiration, minimal ongoing innovation |
| Marketing & Distribution |
10–15% |
Critical for maintaining global presence |
| Regulatory & Compliance |
3–5% |
Increasingly complex, particularly in emerging markets |
3.4. Investment Considerations
- Stable Cash Flows: Due to repeated, high-volume use in diagnostic procedures.
- Market Maturity: Growth primarily driven by volume rather than price increases.
- Pricing Trends: Intense pricing competition among generics, pressure on margins.
- Potential for Portfolio Expansion: Diversification into related imaging agents could offset stagnation.
4. Strategic Analysis
4.1. Opportunities
| Opportunity Type |
Rationale |
| Market Penetration in Asia-Pacific |
Rapidly growing healthcare infrastructure, expanding population base |
| Product Differentiation |
Emphasize safety and enhanced imaging capabilities to retain market share |
| Partnership and Licensing |
Collaborate with regional manufacturers to enhance distribution |
4.2. Threats
| Threats |
Impact |
| Competition from MRI Contrast Agents |
Migration from CT to MRI modality could decrease demand |
| Regulatory Environment Changes |
Stricter safety assessments could increase compliance costs |
| Price War among Generics |
Margin compression reducing profitability |
5. Comparative Performance and Market Positioning
| Aspect |
OMNIPAQUE 140 |
Major Competitors |
| Market Share (Estimate) |
17–20% |
GE's Omnipaque (~23%), Bayer's Ultravist (~20%) |
| Regulatory Approval Stability |
Long-standing |
Established, but varying regional policies |
| Safety Profile |
Iso-osmolar, favorable |
Varying osmolarity, safety concerns with ionic agents |
| Distribution Network |
Extensive, global |
Similar, with regional strengths |
6. Regulatory and Policy Impacts
| Policy Area |
Potential Effect on OMNIPAQUE 140 |
Examples |
| Reimbursement Policies |
Could influence volume growth; reimbursement cuts may limit uptake |
U.S. CMS changes, EU health policies |
| Safety Regulation Stringency |
May require formulation modifications; increase R&D costs |
FDA guidance, EMA updates |
| Intellectual Property Landscape |
Patent expirations, generic entry, price erosion |
Off-patent since 2015[10] |
7. Comparison with Alternative Imaging Modalities
| Modality |
Advantages of Alternatives |
Limitations for Contrast Agents |
| MRI |
No iodine or radiation exposure |
Higher costs, longer scan times |
| Ultrasound |
Real-time, portable |
Limited to soft tissues, operator-dependent |
| Positron Emission Tomography (PET) |
High sensitivity |
Very costly, limited availability |
Implication: Continued reliance on contrast agents like OMNIPAQUE remains critical in current diagnostic protocols.
8. Key Takeaways for Stakeholders
| Insight |
Strategic Implication |
| Market stability due to diagnostic reliance |
Low risk of obsolescence; consistent demand. |
| Aging population enhances demand |
Positioned for sustained growth, especially in mature markets. |
| Generic competition pressures on pricing |
Focus on operational efficiencies and expanding markets. |
| Safety profile as a differentiator |
Leverage safety advancements for market share retention. |
| Emerging markets as growth engines |
Investment in local manufacturing and partnerships essential. |
9. Conclusion
OMNIPAQUE 140 maintains a resilient market position driven by its safety profile, established regulatory approvals, and high-volume demand in diagnostic imaging. While competitive pressures and shifts in diagnostic modalities present challenges, strategic expansion into emerging markets, safety-oriented branding, and potential product portfolio diversification offer pathways for growth. The financial trajectory indicates steady revenue streams with moderate growth, making it a relatively stable asset within the contrast media segment.
10. FAQs
Q1: What is the primary driver of demand for OMNIPAQUE 140?
A: The primary driver is its widespread application in CT imaging, supported by the increasing global prevalence of chronic diseases and aging populations requiring diagnostic procedures.
Q2: How does OMNIPAQUE compare with ionic contrast agents in terms of safety?
A: OMNIPAQUE’s iso-osmolar, non-ionic formulation reduces patient risk of adverse reactions, especially nephrotoxicity, compared to older ionic contrast agents.
Q3: What are the future growth prospects for OMNIPAQUE 140?
A: Growth prospects hinge on expanding in emerging markets, maintaining safety differentiation, and positioning in a landscape with rising MRI preferences by emphasizing its unique safety profile.
Q4: How does patent expiry impact OMNIPAQUE’s market dynamics?
A: Patent expiration has facilitated increased generic competition, leading to pricing pressures but also broadening access due to lower-cost options.
Q5: What regulatory factors could influence OMNIPAQUE’s market stability?
A: New safety regulations, quality standards, and reimbursement policies, especially in key markets like the U.S. and Europe, could influence demand and pricing.
References
[1] MarketsandMarkets, "Contrast Media Market," 2022.
[2] IQVIA, "Global Contrast Media Market Share Report," 2022.
[3] WHO, "Global Aging Population Statistics," 2022.
[4] CDC, "Chronic Disease Trends," 2021.
[5] Radiology Society Annual Reports, 2022.
[6] WHO and national health investment reports, 2021.
[7] OECD Healthcare Policy Reviews, 2022.
[8] MRI contrast agent market studies, 2022.
[9] FDA Drug Safety Communications, 2021.
[10] PatentScope, WIPO, "Iodixanol Patent Expiry," 2015.
